Emerging Resistance in Streptococcus pneumoniae

Séminaire de Pathologie Infectieuse (UCL) 28 juin 2001

Click here to start

Table of Contents

Emerging Resistance in Streptococcus pneumoniae 

Antimicrobial Resistance Mechanisms

?-Lactams 

PPT Slide

PPT Slide

PPT Slide

PPT Slide

Assessing resistance and mortality

PPT Slide

The Alexander Project 1999: S. pneumoniae, Pen-I and Pen-R

Logistic regression analysis of penicillin resistance and mortality, invasive pneumococcal pneumonia

Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia 

In-hospital medical outcomes for patients with pneumococcal pneumonia, adjusted for severity of illness

Proposed NCCLS ceftriaxone/cefotaxime/cefepime susceptibility breakpoint changes

Proposed NCCLS ceftriaxone/cefotaxime/cefepime susceptibility breakpoint changes

Penicillin-resistant S. pneumoniae tend to be resistant to other ?-lactams

PPT Slide

Macrolide Resistance

Ribosome

PPT Slide

Mechanism of Action of MLS Antibiotics

Mechanisms of Resistance 

Target modification: methylation

PPT Slide

Efflux in S. pneumoniae

Correlation between erythromycin MICs and resistance mechanisms

PPT Slide

The Alexander Project 1999: S. pneumoniae, Macrolide Resistance

Why haven’t we seen treatment failures in macrolide resistant pneumococci treated with macrolides?

Macrolide treatment failures with macrolide resistant S. pneumoniae

Fluoroquinolones 

Topoisomerases: critical enzymes in DNA replication

How do fluoroquinolones work

PPT Slide

Targets for the fluoroquinolones

Development of Resistance

Mechanisms of Resistance to Fluoroquinolones

Development of Resistance

Mechanism of Action of Fluoroquinolones

Spontaneous mutation

Burden of pneumococci during infection

Issues

Issues

Clinical Fluoroquinolone and Oral Cephalosporin Failures

Clinical Fluoroquinolone and Oral Cephalosporin Failures

Clinical Fluoroquinolone and Oral Cephalosporin Failures

Fluoroquinolone resistance rates in pneumococci

Decreased susceptibility of S. pneumoniae to fluoroquinolones in Canada

Fluoroquinolone use and PRSF Canada, 1988-1998

CBSN S. pneumoniae MICs for ciprofloxacin, 1993-8

Analysis of ciprofloxacin activity against S. pneumoniae after 10 years use in US

PPT Slide

Implications

Quinolone Activity Against Ciprofloxacin-Resistant S. pneumoniae*

Quinolone Activity Against Ciprofloxacin-Resistant S. pneumoniae*

Quinolone Activity Against Ciprofloxacin-Resistant S. pneumoniae*

Quinolone Activity Against Ciprofloxacin-Resistant S. pneumoniae*

Quinolone Activity Against Ciprofloxacin-Resistant S. pneumoniae*

Issues

PPT Slide

Issues

PPT Slide

What does it mean clinically?

Failure of treatment of pneumococcal pneumonia with levofloxacin

Case 1 

PPT Slide

Case 2 

PPT Slide

Case 3 

Case History

PPT Slide

Course in Hospital

PPT Slide

Case 4

Author: Donald Low 

Email: tulkens@facm.ucl.ac.be

Home Page: http://www.md.ucl.ac.be/seminfect/resume.htm

Download the whole presentation (PDF file; 2.2 Mb)